AOD-9604

Research

AOD-9604 (HGH Fragment 176-191)

Aliases
HGH Fragment 176-191, Anti-Obesity Drug 9604
Administration
Subcutaneous injection

Research and regulatory

Development stage

Phase II trials for obesity discontinued by originator (Metabolic Pharmaceuticals) after failing to beat placebo on the primary endpoint.

Legal and regulatory

Unscheduled research compound; not FDA approved.

Side effects

Generally well-tolerated in trials; efficacy for weight loss not established versus placebo